Innoviva, Inc. (‘Innoviva’) operates as a company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (‘IST’), and a portfolio of strategic investments in other healthcare…
Analysis
Middle-of-the-road
Innoviva, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is attractive. You pay 3.1× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone. At today's price, the market is assuming roughly -21% yearly growth; analysts expect 35%. The price, in other words, assumes less than the experts do.
The trajectory is solid and the balance sheet is adequate. The company scores 18/20 on our value-creation score: strong value creator.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202363
100
2023202420252026
All-time high
100
Jun 2026
All-time low
21
Jan 2024
Average rank
61
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
71
34
24
20
Price/Earnings
36
70
50
89
Price/Book
67
45
41
64
Dividend Yield
1
1
1
1
Value (overall)
74
43
14
53
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.